Brussels: A dispute over medical devices has hardened into one of the sharpest tests of Europe’s trade relationship with China. The European Commission moved to shut Chinese suppliers out of large public tenders for hospital equipment, and Beijing answered in kind, so a quiet procurement quarrel now sits near the centre of the bilateral agenda.
The Commission acted under its International Procurement Instrument, a tool built to pry open foreign markets that treat European firms unfairly. Its first investigation concluded that China had systematically blocked European medical device makers from government contracts, and the Union responded by excluding Chinese bidders from EU tenders above five million euros. The Commission lays out the mechanism on its trade policy page.
Reciprocity drives the whole affair. Brussels argues that it keeps its own procurement markets broadly open while China funnels public money toward domestic champions under a de facto buy-China policy. The instrument, officials insist, aims less to punish than to pressure Beijing into treating European firms as openly as Europe treats Chinese ones.
China read the move as protectionism and retaliated fast, restricting government purchases of European medical devices in turn. That mirror response captures the risk that runs through the Union’s harder trade posture: every lever Brussels pulls invites a matching pull from the other side, and European exporters can end up caught in the squeeze.
The stakes reach well beyond scanners and surgical kit. Medical devices have become a proxy for the larger argument about de-risking, in which the Union tries to defend strategic industries without tipping into open economic conflict. Electric vehicles, rare earths and public contracts all belong to the same widening contest over who sets the terms of access.
Timing raises the temperature. The clash lands as the two powers mark half a century of diplomatic ties, an anniversary that was meant to soothe rather than inflame. Instead it has become a reminder that symbolism rarely survives contact with a concrete grievance, and that goodwill summits now open under a cloud of unresolved disputes.
European firms feel the exposure keenly. Many earn substantial revenue inside China and fear that a cycle of tit-for-tat will cost them a market they cannot easily replace. Their lobbyists urge negotiation over escalation, warning that reciprocity can curdle into mutual damage if neither capital blinks.
For now Brussels holds its line, betting that measured pressure will bring Beijing back to the table rather than harden its resolve. Whether that bet pays off will say a great deal about the Union’s ability to wield its new trade weapons with precision, and about whether the two giants can manage their rivalry without letting a hospital contract set the tone for everything else.
